Scarica l'app Stockscreener
24.56
0.18%
-0.0534
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer (PFE) Expands Patient Access With Eliquis (Apixaban) Direct Purchase Program - simplywall.st
Pfizer’s EPIC-Peds Study: A Potential Game-Changer for Pediatric COVID-19 Treatment - TipRanks
Pfizer’s Phase 1 Study on PF-07941944: Key Insights for Investors - TipRanks
Pfizer’s Pediatric Leukemia Study: Implications for BESPONSA’s Market Potential - TipRanks
Bristol Myers, Pfizer to offer Eliquis at a discount for some patients - BioPharma Dive
Major drugmakers offer big discount on blood thinner Eliquis - Fox Business
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters
Pfizer Inc.'s (NYSE:PFE) recent 3.7% pullback adds to one-year year losses, institutional owners may take drastic measures - Yahoo Finance
Lifestyle Drugs Market Future Business Opportunities - openPR.com
How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest
Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg
BMS-Pfizer alliance to offer Eliquis at 40% discount to cash-paying patients - Investing.com Canada
Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan
Exclusive | Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount - The Wall Street Journal
Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours - Stocktwits
4 High-Yield Large-Caps With Dividend Risk and Opportunity in Focus - Investing.com
Pfizer’s Latest Clinical Study: A New Hope for Advanced Melanoma Treatment? - TipRanks
Pfizer’s INLYTA® Study Completion: Real-World Insights and Market Impact - TipRanks
Pfizer’s Hemophilia Study Completion: Market Implications and Insights - TipRanks
AbbVie and Pfizer’s Promising Study on Lung Cancer Treatment: A Market Game-Changer? - TipRanks
Pfizer’s BeneFIX Study Completion: Market Implications and Insights - TipRanks
Pfizer Subsidiary Recalls Bicillin L-A; South Dakota Department of Health Advises Caution - mykxlg.com
Jim Cramer Says Pfizer Needs a Catalyst - MSN
NYC Mayor Race: Mamdani Talks 'Intifada', Taxes in Grilling by Business Leaders - Bloomberg
Pfizer (PFE) Shares Cross 7% Yield Mark - Nasdaq
Japan discards 2.5m doses of expired COVID drugs from Pfizer, Merck - Nikkei Asia
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings? - MSN
Pfizer Plummets 2.4%—Is Oncology's Growth Spree Over? - AInvest
Morningstar Reduces Moat Rating For Pfizer (PFE) To Narrow - Insider Monkey
Ex-Pfizer Doctor Tells Congress He Didn’t Delay Covid Shot Data - Bloomberg
Pfizer describes new STAT6 inhibitors - BioWorld MedTech
She helped launch Pfizer's COVID-19 vaccine in the depths of the pandemic. Now, she's planning her next act. - Business Insider
TD Cowen Adjusts Price Target on Pfizer to $30 From $28, Maintains Hold Rating - MarketScreener
Oxford BioDynamics shares jump 118% after Pfizer validates blood-based cancer biomarker technology - Proactive Investors
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook - Benzinga
Pfizer’s Phase 3 Study on PF-06821497: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
Pfizer’s RSV Vaccine Trial: A Potential Game-Changer for Infants with HIV - TipRanks
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
Pfizer (PFE) Reports XTANDI Shows Life-Extending Benefits - Insider Monkey
Pfizer Earnings Preview: What to Expect - MSN
Pfizer's Legal Crossroads: Navigating Risks and Opportunities in Pharma Litigation - AInvest
Pfizer Inc. - Britannica
Pfizer’s Study on Rimegepant and Pregnancy: What Investors Need to Know - TipRanks
Pfizer’s New Phase 1 Study: A Potential Game-Changer in Cancer Treatment? - TipRanks
Pfizer’s Promising Migraine Study in Adolescents: What Investors Should Know - TipRanks
Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Pediatric Eczema - TipRanks
Pfizer’s New Acne Treatment Study: A Potential Game-Changer? - TipRanks
Pfizer’s Promising Phase 3 Study on Ritlecitinib for Vitiligo: Market Implications - TipRanks
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Pfizer’s EPIC-Peds Study: New Insights into Pediatric COVID-19 Treatment - TipRanks
Pfizer shakes up corporate affairs function; Bloomberg confident newsroom will grow despite job cuts - Ragan Communications
Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony - Benzinga
Pfizer: conclusive trial in prostate cancer - MarketScreener
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Promising Update - TipRanks
Pfizer Takes Aim At Moderna's Leftover MRNA Protections - Law360
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study - Benzinga
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer for Rimegepant - TipRanks
Pfizer’s New Study on PF-07985045: A Potential Game-Changer in Cancer Treatment? - TipRanks
Pfizer’s Cibinqo Study: A Closer Look at Its Market Potential - TipRanks
Pfizer’s Promising Migraine Study: A Potential Game-Changer for Young Patients - TipRanks
Pfizer’s New COVID-19 Treatment Study: A Potential Game Changer? - TipRanks
Pfizer’s Real-World Study on Abrocitinib: Key Insights for Investors - TipRanks
Pfizer’s New Phase 1 Study: A Potential Game-Changer for Atopic Dermatitis - TipRanks
Pfizer Stock Just Broke A Monthslong Bear Streak. Is It Now A Buy? - Investor's Business Daily
Pfizer’s Isavuconazole Study: A Boost for Chinese Market Expansion - TipRanks
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Breakthrough for Atopic Dermatitis - TipRanks
0.06%
0.78%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):